Biopharmaceutical Stock

Rayno Biopharmaceutical Stock Portfolio Up 30%

What bear market?

Rod Raynovich

My biotech picks were published in Genetic Engineering News (GEN) in February 2008. My strategy was to allocate 25% in one ETF(XBI), 50% in large caps and 25% in small caps biotechs. My proprietary system is based on technicals, core technology and company financials. So despite all the volatility in 2008 and crowded trades in materials,energy, retail,real estate and the death spiral for financial stocks the safe haven was Biopharm and Medtech.
Read the complete GEN Wall Street Roundup story here.

The main drivers of this market as reviewed in the article were M&A, product announcements, and value. The biotechnology market is coming up on its strongest seasonality the 4th quarter a period of bullishness for smaller caps.

Here are the picks:

Stock Company Weighting 2/1/08 8/15/08 % return YTD Ave return
XBI ETF S&P Bio 25% 55 69 25.5 25.50%
Large Cap Buys 50% 31%
AMGN AMGEN 47 65 38.45
CELG Celgene 59 75.9 28.6
DNA Genentech 70 98.25 40.35
PFE Pfizer 22 20 -9.3
Small Cap Buys 25% 34%
ALNY Alnylam 30 34.75 15.8
CBST Cubist 18 23.55 30.8
CRA Celera 15 14.5 -3.33
EPIX Epix 3 1.92 -36
ISIS Isis 15 19.1 27.2
MATK Martech 28 37.7 34.7
MYGM Myriad Genetics 40 65.5 63.75
SGEN Seattle Genetics 9 12.15 34.9
VPHM ViroPharma 9 13.9 54.5
Return YTD +30%